Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10234 vs TDF in chronic hepatitis B
CTR20180816Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir amibufenamide in Chronic Hepatitis B (CHB), sponsored by Hengrui Therapeutics. Started Dec 2018; status: completed.
02
Drugs
tenofovir amibufenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20180816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180816.